FDA's Pre- and Post-marketing Safety Programs Top Science Board Agenda

The FDA's premarketing and postmarketing safety programs from drugs and biologics will be at the top of the agenda when the agency's Science Board convenes this month.

The April 15 meeting will focus on two main topics: 1) the FDA's safety programs, and 2) good manufacturing practices for vaccines, blood, cell tissue and gene products.

The meeting will take place at the FDA's main office in Rockville, Md., from 8:30 a.m. to 5:00 p.m.

For more information, go to http://www.fda.gov/OHRMS/DOCKETS/98fr/2005-4136-nm00001.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/2005-4136-nm00001.pdf).